Did SCOTUS slam the door on personalized medicine with Prometheus ruling?
This article was originally published in Scrip
Executive Summary
In a 20 March ruling that sent shockwaves throughout the biotech community – with potential repercussions for time to come for personalized medicine – the US Supreme Court invalidated diagnostic methods patents held by Prometheus Laboratories, opening the door for rival Mayo Clinic to market its own test without fear of patent infringement.